Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Antiviral Res. 2020 Jan 22;174:104702. doi: 10.1016/j.antiviral.2019.104702

Table 7.

CCHFV vaccines evaluated against strains other than IbAr10200.

Knockout Vaccine Antigen Vaccine virus Schedule Dose/route; adjuvant (if applicable) Challenge post-vaxa Challenge strain Challenge dose/route Efficacy (survival) Ref.
IFNAR−/− Plasmid DNA N Ank-2 P/B, 2 wk interval 50 μg DNA IM 2 wk Ank-2 1000 TCID50/IP 100% Farzani et al. (2019a)
N Ank-2 P/B, 2 wk interval 40 μg DNA IM + 10 μg CD24 IM 2 wk Ank-2 1000 TCID50/IP 100% Farzani et al. (2019a)
VRP L, N, GPC IbAr10200 N, L + Oman GPC P 105 TCID50/SC 4 wk Turkey-200406546 100 TCID50/SC 100% Spengler et al. (2019)
L, N, GPC IbAr10200 N, L + Oman GPC P 105 TCID50/SC 4 wk Oman-199723179 100 TCID50/SC 100% Spengler et al. (2019)
Inactivated, purified virus pellet L, N, GPC Turkey-Kelkit06 P/B/B, 3 wk intervals 20, or 40 μg/IP; alum 2 wk Turkey-Kelkit06 1000 PPFU/IP 80% Canakoglu et al. (2015)
L, N, GPC Turkey-Kelkit06 P/B/B, 3 wk intervals 5 μg/IP; alum 2 wk Turkey-Kelkit06 1000 PPFU/IP 60% Canakoglu et al. (2015)
BoHV-4 N Ank-2 P/B, 2 wk interval 102 TCID50 IP 2 wk Ank-2 1000 TCID50/IP 100% Farzani et al. (2019b)
mRNA N Ank-2 P 25 μg IM 4 wk Ank-2 1000 tcid50/ip 50% Farzani et al. (2019c)
N Ank-2 P/B, 2 wk interval 25 μg IM each dose 2 wk Ank-2 1000 TCID50/IP 100% Farzani et al. (2019c)
STAT1−/− rVSV (replication competent) GPC IbAr10200 P or P/B (2 wk interval) 107 PFU/IP 3 wk Turkey-200406546 50 PFU/IP 100% (P/B only) Rodriguez et al. (2019)
a

refers to time since last vaccine dose administered.; B, boost; BoHV-4, bovine herpesvirus type 4; FFU, focus-forming units; ID, intradermal (between shoulders); IFN, interferon; IFU, infectious units; IM, intramuscular; IN, intranasal; IP, intraperitoneal; LD50, 50% lethal dose in IFNAR−/− mouse; P, prime; SC, subcutaneous; PPFU, pseudo plaque-forming units; PFU, plaque-forming units; rVSV, recombinant vesicular stomatitis virus; TCID50, tissue culture infectious dose 50%; VRP, viral replicon particle; WT, wild-type.